About
Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.
The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules.
Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist.
Kailera Therapeutics, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:KLRA
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Profitability & Returns
Margins and return on capital
Analyst Estimates
Street consensus and price targets
Risk Metrics
Volatility versus the market
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-05-13 | $22.50 | $23.39 | $21.00 | $21.11 | $21.11 | -1.39 | 349,600 |
| 2026-05-12 | $23.41 | $23.62 | $22.13 | $22.30 | $22.30 | -1.11 | 359,200 |
| 2026-05-11 | $21.52 | $23.20 | $21.52 | $22.93 | $22.93 | +1.41 | 482,900 |
| 2026-05-08 | $22.52 | $24.27 | $21.22 | $21.47 | $21.47 | -1.05 | 446,200 |
| 2026-05-07 | $24.66 | $24.74 | $22.44 | $22.47 | $22.47 | -2.19 | 279,900 |
| 2026-05-06 | $24.22 | $25.70 | $23.88 | $24.70 | $24.70 | +0.48 | 531,200 |
| 2026-05-05 | $25.01 | $25.50 | $23.80 | $24.26 | $24.26 | -0.75 | 425,200 |
| 2026-05-04 | $24.95 | $25.32 | $24.22 | $25.09 | $25.09 | +0.14 | 729,900 |
| 2026-05-01 | $25.02 | $25.55 | $24.04 | $25.15 | $25.15 | +0.13 | 551,200 |
| 2026-04-30 | $24.51 | $25.41 | $24.12 | $25.00 | $25.00 | +0.49 | 462,500 |
| 2026-04-29 | $23.95 | $25.00 | $23.28 | $24.76 | $24.76 | +0.81 | 681,100 |
| 2026-04-28 | $23.27 | $24.32 | $22.95 | $23.82 | $23.82 | +0.55 | 461,400 |
| 2026-04-27 | $22.26 | $23.64 | $20.87 | $23.51 | $23.51 | +1.25 | 1,070,500 |
| 2026-04-24 | $24.70 | $25.30 | $22.10 | $22.47 | $22.47 | -2.23 | 1,209,800 |
| 2026-04-23 | $24.25 | $25.48 | $24.13 | $25.08 | $25.08 | +0.83 | 3,995,800 |
| 2026-04-22 | $25.17 | $25.75 | $23.65 | $24.30 | $24.30 | -0.87 | 891,900 |
| 2026-04-21 | $24.87 | $25.79 | $23.70 | $25.22 | $25.22 | +0.35 | 843,100 |
| 2026-04-20 | $26.50 | $28.23 | $23.69 | $24.61 | $24.61 | -1.89 | 1,341,000 |
| 2026-04-17 | $26.00 | $27.50 | $23.70 | $26.00 | $26.00 | 0.00 | 8,114,300 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| SCHEDULE 13D | Apr 23, 2026 | Filing |
| SCHEDULE 13D | Apr 23, 2026 | Filing |
| 8-K | Apr 20, 2026 | Current Report |
| 424B4 | Apr 17, 2026 | Prospectus |
| S-8 | Apr 17, 2026 | Securities to be offered to employees in employee benefit plans |
| EFFECT | Apr 16, 2026 | Notice of Effectiveness |
| S-1MEF | Apr 16, 2026 | Registration adding securities to prior Form S-1 registration |
| CERT | Apr 15, 2026 | Certification by an exchange approving securities for listing |
| 8-A12B | Apr 14, 2026 | Registration of securities |
| S-1/A | Apr 13, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Ronald C. Renaud, Jr.
President, Chief Executive Officer and Director
Scott Akamine
Chief Legal Officer and Secretary
Paul Burgess
Chief Operating Officer and Chief Business Officer
Paula Cloghessy
Chief People Officer
Jamie Coleman
Chief Commercial Officer
Douglas Pagán
Chief Financial Officer
Scott Wasserman, M.D.
Chief Medical Officer
John F. Milligan, Ph.D.
Chairman
Frank Clyburn, Jr.
Director
Michael Gladstone
Director
